Bildyos and Bilprevda have the same indications as the reference products Prolia and Xgeva and are expected to be available later this year.

Shanghai Henlius Biotech and Organon have received permission from the Food and Drug Administration for Bildyos ...

"Today's approval of XGEVA illustrates what is possible when scientific innovation, commitment and investment come together to advance medicine," said Kevin Sharer, chairman and chief executive ...

The FDA approved Bildyos and Bilprevda as biosimilars to Prolia and Xgeva, expanding bone care options for osteoporosis, cancer and more.

SEATTLE — Among bariatric surgery patients treated with denosumab to counter bone loss, follow-up treatment with zoledronic ...

Shanghai Henlius Biotech and Organon (NYSE:OGN) said that they have received approval from the U.S. FDA for two new ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan's The Searle Company Limited (PSX: SEARL, hereinafter "Searle") jointly announced that two ...

FDA’s boxed warning on denosumab follows study results showing increased and early risks of severe hypocalcemia in patients on dialysis. The Food and Drug Administration (FDA) has added a new boxed ...

US FDA approves Henlius & Organon’s Bildyos and Bilprevda, biosimilars to Prolia and Xgeva respectively: Shanghai, China Wednesday, September 3, 2025, 12:00 Hrs [IST] Shanghai H ...